The table below shows Axsome Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$638.50M
$385.69M
$270.60M
$0.00
-
-
Cost of revenue
-
-
-
$5.20M
-
-
Gross profit
-
-
-
-
-
-
R&D
$183.28M
$187.08M
$97.94M
$57.95M
$58.06M
$70.24M
SG&A
AXSM annual revenue (10-K history)
Axsome Therapeutics, Inc. reported annual revenue of $638.50M for fiscal year 2025. That is up 65.5% from $385.69M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
